Croda International 6.6 % Cum Pref Stock Earnings Reports

Croda reported FY2025 results with constant-currency sales up 7% to £1.7bn and adjusted operating profit up 8% to £295m. Free cash flow improved to £162m, net debt fell to £524m (1.3x EBITDA) and the full-year dividend was raised slightly to 111p. Management highlighted renewed top-line momentum across Consumer Care (notably Fragrances & Flavors, Beauty Actives) and Life Sciences (Crop Protection recovery, Pharma excipients), and improved Net Promoter Scores reflecting stronger customer trust. Margins remain below target but showed recovery (second-half operating margin 17.6%), helped by transformation savings; the company plans total annualized savings of £100m and working capital reduction of £50m by 2028. There were significant one-off/non-cash exceptional charges (£150m) including a £45m impairment of the Lamar lipid site, which has been placed on standby to eliminate future exposure. Croda set a 2026 near-term guide of organic growth of 3–6% (group) with sales split roughly 50/50 H1/H2 and reiterated a three-year financial framework to 2028 targeting: organic group growth of ~3–6% p.a., adjusted operating margin >20% by 2028, free cash flow >12% of sales and ROIC >10%. Capital allocation priorities are organic investment first, maintaining ordinary dividends (40–50% payout policy target), modest bolt-on M&A (<£10m typical), and keeping net debt between 1–2x EBITDA with potential for additional shareholder returns as cash generation increases.